Fiche publication
Date publication
mars 2026
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, Kött J, Zell T, Amaral T, Ascierto PA, Corrie P, Dummer R, Eggermont A, Guo J, Hassel JC, Jalving M, Johnson DB, Kandolf L, Kirkwood JM, Lebbé C, Lee R, Long GV, Lorigan P, Malvehy J, Mangana J, Mohr P, Patel SP, Rizos H, Robert C, Schadendorf D, Sondak VK, Svane IM, Wainstein A, Zager JS, Pantel K, Hauschild A, Gebhardt C,
Lien Pubmed
Résumé
Circulating tumor DNA (ctDNA) is a promising biomarker in melanoma, with higher sensitivity for tumor burden detection than conventional diagnostics. While well established in research, clinical routine implementation remains pending. Key global questions concern optimal clinical applications and barriers to adoption.
Mots clés
Circulating tumor DNA (ctDNA), Expert survey, Liquid biopsy, Melanoma, Minimal residual disease (MRD)
Référence
Eur J Cancer. 2026 03 19;239:116676
